Patients with atopic dermatitis (AD) were treated with diode low reactive level laser therapy 
Introduction
Atopic dermatitis (AD) is one of the common chronic skin diseases in which a variety of immunological dis turbances have been described.1,2 Cyclosporin A,3 gamma interferon,4 and interleukin 25 were recently suggested for the management of the disease. They all act on some component of the immunological mechanism which provoke eczematous reactions. But because of side effects, we do not use these therapies as our first choice. Steroid ointment is still widely used for the treatment of AD. Steroid rosacea sometimes appears during the prolonged application of steroids. In the present study, we used a GaA1As 830nm diode laser for the treatment of patients with atopic dermatitis. Immuno histological examination was also performed before and after LLLT.
Patients and Methods

Patients
From November 1991 to April 1993, 112 AD patients were treated with LLLT. Mean age was 18 years (3 to 45). All patients (62 women and 50 men) participating in this study had atopic dermatitis as classified according to the criteria of Hanifin and Rajka. 6 The following basic features were present: A chronic or chronically relapsing dermatitis and pruritis. They were all allergic to two or more different allergens, had positive skin reactions to these allergens, elevated total immunoglobulin (lg)E levels and positive radio-allergo-sorbent tests (RASTs) for the relevant allergens. The patients had not taken oral steroids before and after LLLT.
A diode laser system (Matsushita Electrical Company. Osaka Japan) was used for the treatment of AD patients. The system emits a 60mW continuous wave beam at a wave length of 830nm. We treated the patients once a week with the diode laser for 120 sec. per 100cm2 of skin lesion on the trunk, face or extremities. Use of internal or external medicines were continued without change before and after LLLT. MHC class II, ICAM-1 and CD1 expression on epidermal cells before and after LLLT Before LLLT, HLA-DR positive dendritic cells were detected in the epidermis. The majority of keratinocytes were negative for HLA-DR staining. Almost all dermal infiltrating cells were HLA-DR positive. After LLLT, HLA-DR positive dendritic cells decreased remarkably in number compared with before LLLT. HLA-DR posi tive dermal infiltrating cells also decreased after LLLT. ICAM-1 expression was detected focally on keratinocytes before LLLT. The majority of dermal infiltrating cells expressed ICAM-1. ICAM-1 expression on keratinocytes and dermal infiltrating cells almost disappeared after LLLT. The numbers of CD1 positive dendritic epidermal cells showed no difference before and after the therapy.
Discussion
Diode lasers were at first restricted to gallium arsenide (GaAs) systems, which usually produced a 904nm beam.
GaAs systems were typically difficult to run for long periods because of the propensity of the chip to overheat. Japan Medical Laser Laboratory (JMLL), together with Matsushita Electrical Company worked on developing a new gallium aluminium arsenide (GaA1As) system for medical application, producing an 830nm beam with 15mW. The GaAlAs chip could run in a continuous wave without overheating. This therapy is generally referred as low reactive level laser therapy (LLLT). 8 The reports of LLLT for clinical application have been in creasing. 8, 9 In the present study we used LLLT on the patients with AD. pruritus but their efficacy is limited. Recently, psoralen ultraviolet A (PUVA) therapy" has been used to treat patients with chronic severe AD and who have failed to respond to ordinary treatments. The mechanism of action of PUVA therapy is thought to be anti-inflammatory by reducing the function of antigen-presenting cells . How ever, there is a risk of development of skin cancer . Therefore, the dosage and duration of PUVA therapy should be kept to a minimum. The mechanism of action of LLLT seems similar to PUVA therapy , because the expression of MHC class II antigen and ICAM-1 on the epidermal cells decreased after LLLT . The number of CD1 positive cells did not change before and after LLLT . From these findings we consider that the effect of the mechanism of LLLT is anti-inflammatory , without any tissue damage. There is no report about the development of skin cancer after LLLT. We therefore consider that LLLT is safer than PUVA therapy . The patients with AD manifest abnormalities in immune regulation . Based on these findings, immunomodulator (interleukin -2 , i nterferon-gamma) therapy have recently been re ported.4,5 As the therapeutic effect is transient and immunomodulator therapy is rather toxic to the patients (chills, malaise, hepatomegaly, edema, pleural effusion), the potential harm of immunomodulators therapy should be seriously considered in a non-fatal disease such as AD. In the present study, we treated 112 AD patients with LLLT. There were no side effects during and after LLLT. The treatment was effective for the decrease in itchy sensation in 71% of the cases. Skin eruptions improved in 62% of the cases. Based on this evidence, we consider that LLLT may become a new therapy of choice for the treatment of AD.
